Cardiac Transplantation in HIV-positive Patients: Are We There Yet?

Journal of Heart and Lung Transplantation

Volumn 26, Issue 2, 2007, Pages 103-107

  Jahangiri, Bijan ^a   Haddad, Haissam ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; PROTEINASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CARDIOTOXICITY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; HEALTH CARE PERSONNEL; HEART TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SURVIVAL; TREATMENT CONTRAINDICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HIV SEROPOSITIVITY; HUMANS;

EID: 33846354185     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.11.007     Document Type: Article

References (50)

1. Centers for Disease Control (CDC). Update on acquired immune deficiency syndrome (AIDS)-United States. MMWR Morbid Mortal Wkly Rep 31 (1982) 507-508
2. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al., HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338 (1998) 853-860
3. Babiker A., Bhaskaran K., Darbyshire J., Pezzotti P., Porter K., and Walker S.A. CASCADE collaboration determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362 (2003) 1267-1274
4. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
5. Szczech L.A., Gupta S.K., Habash R., et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 66 (2004) 1145-1152
6. Herman E.S., and Klotman P.E. HIV-associated nephropathy: epidemiology, pathogenesis, and treatment. Semin Nephrol 23 (2003) 200-208
7. Szeto C.C., and Chow K.M. Nephrotoxicity related to new therapeutic compounds. Renal Fail 27 (2005) 329-333
8. Izzedine H., Launay-Vacher V., and Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 (2005) 804-817
9. Brau N. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. J Antimicrob Chemother 56 (2005) 991-995
10. Fung J., Eghtesad B., Patel-Tom K., DeVera M., Chapman H., and Ragni M. Liver transplantation in patients with HIV infection. Liver Transplant 10 suppl 2 (2004) S39-S53
11. Roland M.E., and Stock P.G. Review of solid-organ transplantation in HIV-infected patients. Transplantation 75 (2003) 425-429
12. Sulkowski M.S. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 23 (2003) 183-194
13. Sulkowski M.S., Thomas D.L., Mehta S.H., Chaisson R.E., and Moore R.D. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35 (2002) 182-189
14. Lesens O., Deschenes M., Steben M., Belanger G., and Tsoukas C.M. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 179 (1999) 1254-1258
15. Benhamou Y., Bochet M., Di Martino V., et al., The Multivirc Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 30 (1999) 1054-1058
16. Barbarinia G., and Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 17 suppl 1 (2003) S46-S50
17. Zareba K.M., and Lipshultz S.E. Cardiovascular complications in patients with HIV infection. Curr Infect Dis Rep 5 (2003) 513-520
18. Rerkpattanapipat P., Wongpraparut N., Jacobs L.E., and Kotler M.N. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 160 (2000) 602-608
19. Cotton P. AIDS giving rise to cardiac problems. JAMA 263 (1990) 2149
20. Passalaris J.D., Sepkowitz K.A., and Glesby M.J. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 31 (2000) 787-797
21. Palacios R., Santos J., Garcia A., et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med 7 (2006) 10-15
22. Fantoni M., Autire C., and Del Borgo C. Drugs and cardiotoxicity in HIV and AIDS. Ann NY Acad Sci 946 (2001) 179-199
23. Solorzano Santos F., Gochicoa Rangel L.G., Palacios Saucedo G., Vazquez Rosales G., and Miranda Novales M.G. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors. Arch Med Res 37 (2006) 129-132
24. Henry K., Melroe H., Huebsch J., et al. Severe premature coronary artery disease with protease inhibitors. Lancet 351 (1998) 1328
25. Behrens G., Schmidt H., Meyer D., Stoll M., and Schmidt R.E. Vascular complications associated with use of HIV protease inhibitors. Lancet 351 (1998) 1958
26. Gallet B., Pulik M., Genet P., Chedin P., and Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet 351 (1998) 1958-1959
27. Vittecog D., Escaut L., and Monsuez J.J. Vascular complications associated with use of HIV protease inhibitors. Lancet 351 (1998) 1959
28. Young A.M., Dhillon T., and Bower M. Cardiotoxicity after liposomal anthracyclines. Lancet Oncol 5 (2004) 654
29. Chen Y., Brennessel D., Walters J., Johnson M., Rosner F., and Raza M. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 137 (1999) 516-521
30. Fisher S.D., Easley K.A., Oray E.J., et al., Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. Am Heart J 150 (2005) 439-447
31. Barbaro G. Pathogenesis of HIV-associated heart disease. AIDS 17 suppl 1 (2003) S12-S20
32. Barbaro G. HIV-associated cardiomyopathy etiopathogenesis and clinical aspects. Herz 30 (2005) 486-492
33. Tzakis A.G., Cooper M.H., Dummer J.S., Ragni M., Ward J.W., and Starzl T.E. Transplantation in HIV+ patients. Transplantation 49 (1990) 354-358
34. Roland M., Carlson L., and Stock P. Solid organ transplantation in HIV-infected individuals. AIDS Clin Care 14 (2002) 59-63
35. Calabrese L.H., Albrecht M., Young J., et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 348 (2003) 2323-2328
36. Bisleri G., Morgan J.A., Deng M.C., Mancini D.M., and Oz M.C. Should HIV-positive recipients undergo heart transplantation?. J Thorac Cardiovasc Surg 126 (2003) 1639-1640
37. Mancini M.M., and Kunavarapu C. Recipient selection. In: Edwards N.M., Chen J.M., and Mazzeo P.A. (Eds). Cardiac transplantation (2004), Humana Press, Totowa, NJ 1-18
38. Mullen M.A., Kohut N., Sam M., Blendis L., and Singer P.A. Access to adult liver transplantation in Canada: a survey and ethical analysis. Can Med Assoc J 154 (1996) 337-342
39. Deng M.C., Smits J.M., De Meester J., Hummel M., Schoendube F., and Scheld H.H. Heart transplantation indicated only in the most severely ill patient: perspectives from the German heart transplant experience. Curr Opin Cardiol 16 (2001) 97-104
40. Ragni M.V., Belle S.H., Im K., Neff G., Roland M., Stock P., et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 188 (2003) 1412-1420
41. Freudenberger R.S., Boruchoff S.E., and Anderson M.B. Policies of U.S. heart transplant programs regarding transplantation of human immunodeficiency-positive patients. J Heart Lung Transplant 23 (2004) 785
42. Sulkowski M.S., Moore R.D., Mehta S.H., Chaisson R.E., and Thomas D.L. Hepatitis C and progression of HIV disease. JAMA 288 (2002) 199-206
43. Ockenga J., Tillmann H.L., Trautwein C., Stoll M., Manns M.P., and Schmidt R.E. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 27 (1997) 18-24
44. Frassetto L., Baluom M., Jacobsen W., et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 80 (2005) 13-17
45. Antonini M., Ettorre G.M., Vennarecci G., et al. Anti-retrovirals and immunosuppressive drug interactions in a HIV-positive patient after liver transplantation. Hepatogastroenterology 51 (2004) 646-648
46. Roland M.E., and Havlir D.V. Responding to organ failure in HIV-infected patients. N Engl J Med 348 (2003) 2279-2281
47. Aberg J.A., Zackin R.A., Brobst S.W., et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 21 (2005) 757-767
48. Stock P.G., Roland M.E., Carlson L., et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 76 (2003) 370-375
49. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU concerted action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 355 (2000) 1131-1137
50. Kaplan J.E., Hanson D.L., Jones J.L., et al. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS 15 (2001) 1831-1836